Gottsegen National Cardiovascular Center

The Gottsegen National Cardiovascular Center’s Adult Cardiac Surgery department is advancing research in cardiovascular diseases, focusing on conditions such as heart failure, myocardial infarction, coronary artery disease, and hypertrophic cardiomyopathy. Ongoing studies aim to test innovative therapies, improve risk assessment, and enhance outcomes for patients with complex cardiac pathology.

• Evaluation of novel treatments for acute heart failure and reduced ejection fraction
• Investigation of therapies targeting elevated lipoprotein(a) to lower cardiovascular risk
• Trials assessing revascularization strategies and residual ischemic burden in coronary bypass surgery
• Studies of combination drugs to reduce major adverse cardiovascular events in patients with diabetes and hypertension
• Research on agents that improve myocardial structure in obstructive hypertrophic cardiomyopathy

These programs reflect the center’s commitment to translating cutting‑edge science into safer, more effective care for patients across Hungary and Europe.

Within the same facility, investigators are dedicated to respiratory tract diseases, particularly pulmonary arterial hypertension (PAH). Clinical work includes testing triple‑therapy regimens, assessing long‑term safety of emerging agents, and extending research to pediatric populations to improve survival and quality of life.

• Comparison of initial triple therapy versus double oral therapy in adult PAH patients
• Long‑term safety extensions of oral agents such as ralinepag for PAH
• Pediatric studies evaluating preservative‑free treprostinil and macitentan
• Platform trials monitoring safety and tolerability of various PAH interventions
• Exploration of new pathways to reduce disease progression in PAH group I

The site’s multidisciplinary approach leverages its cardiac surgery expertise to address the intersecting challenges of heart and lung vascular disease.